Patients with advanced hepatocellular carcinoma (HCC) have a longer overall and progression-free survival when treated with a combination of bevacizumab and PD-L1 blocking antibody atezolizumab, compared to those treated with sorafenib [137]. This evidence concerns the gene CD274 and hepatocellular carcinoma.